Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: Implications for understanding drug efficacy and toxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 12, 2015, Pages 1821-1837

  Koo, Seok Hwee ^a,b   Lo, Ying Li ^a   Yee, Jie Yin ^a   Lee, Edmund Jon Deoon ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

drug transporters; efficacy; epigenetics; genetics; toxicity; variable expression

Indexed keywords

ABC TRANSPORTER; CARRIER PROTEIN; SOLUTE CARRIER TRANSPORTER; UNCLASSIFIED DRUG; DRUG; MESSENGER RNA;

CELL SPECIFICITY; DRUG EFFICACY; DRUG TOXICITY; GENE EXPRESSION PROFILING; HEREDITY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REVIEW; ANIMAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; RNA, MESSENGER;

EID: 84949314485     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1104298     Document Type: Review

References (166)

1. Oostendorp RL, Beijnen JH, Schellens JH. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev. 2009; 35: 137-147.
2. Mikkaichi T, Suzuki T, Tanemoto M., et al. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet. 2004; 19: 171-179.
3. Sai Y, Kaneko Y, Ito S., et al. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos. 2006; 34: 1423-1431.
4. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003; 1609: 1-18.
5. Stefkova J, Poledne R, Hubacek JA. ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res. 2004; 53: 235-243.
6. Tsuji A. Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002; 17: 253-274.
7. Masuda S. Functional characteristics and pharmacokinetic significance of kidney-specific organic anion transporters, OAT-K1 and OAT-K2, in the urinary excretion of anionic drugs. Drug Metab Pharmacokinet. 2003; 18: 91-103.
8. Nakamura N, Masuda S, Takahashi K., et al. Decreased expression of glucose and peptide transporters in rat remnant kidney. Drug Metab Pharmacokinet. 2004; 19: 41-47.
9. Kanai Y, Endou H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J Toxicol Sci. 2003; 28: 1-17.
10. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001; 42: 1007-1017.
11. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11: 1156-1166.
12. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2: 48-58.
13. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006; 580: 2903-2909.
14. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004; 21: 25-51.
15. Hediger MA, Romero MF, Peng JB., et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch. 2004; 447: 465-468.
16. SLC Tables. Bioparadigms. 2004. Switzerland: Institute of Biochemistry and Molecular Medicine, University of Bern. [. cited 2015 April 7[. Available from: http://slc.bioparadigms.org/.
17. Belinsky M, Chen ZS, Shchaveleva I., et al. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002; 62: 6172-6177.
18. Chen ZS, Hopper-Borge E, Belinsky MG., et al. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003; 63: 351-358.
19. Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and-sensitivity of tumor cells. Cancer Lett. 2006; 239: 168-182.
20. Nakanishi T. Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics. 2007; 4: 241-254.
21. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007; 26: 183-201.
22. Ishida N, Kawakita M. Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). Pflugers Arch. 2004; 447: 768-775.
23. Sarangi A, Bupp K, Roth MJ. Identification of a retroviral receptor used by an envelope protein derived by peptide library screening. Proc Natl Acad Sci USA. 2007; 104: 11032-11037.
24. Damme K, Nies AT, Schaeffeler E., et al. Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. Drug Metab Rev. 2011; 43: 499-523.
25. Ito K, Suzuki H, Horie T., et al. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res. 2005; 22: 1559-1577.
26. Groneberg DA, Nickolaus M, Springer J., et al. Localization of the peptide transporter PEPT2 in the lung: Implications for pulmonary oligopeptide uptake. Am J Pathol. 2001; 158: 707-714.
27. Daniel H, Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 2004; 447: 610-618.
28. Van Aubrel RA, Masereeuw R, Russel FG. Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol. 2000; 279: F216-32.
29. Wright SH, Dantzler WH. Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev. 2004; 84: 987-1049.
30. Van Aubrel RA, Smeets PH, Peters JG., et al. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2000; 13: 595-603.
31. Schaub TP, Kartenbeck J, Konig J., et al. Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephro. 1997; 8: 1213-1221.
32. Le Floch R, Chiche J, Marchiq I., et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci USA. 2011; 108: 16663-16668.
33. Fujiwara K, Yoshizaki Y, Shin M., et al., et al. Immunocytochemistry for vancomycin using a monoclonal antibody that reveals accumulation of the drug in rat kidney and liver. Antimicrob Agents Chemother. 2012; 56: 5883-5891.
34. Nagai J, Takano M. Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways. Biochem Pharmacol. 2014; 90: 331-337.
35. Lee SH, Lee MS, Lee JH., et al. MRP1 polymorphisms associated with citalopram response in patients with major depression. J Clin Psychopharmacol. 2010; 30: 116-125.
36. Chen P, Yan Q, Xu H., et al. The effects of ABCC2 G1249A polymorphism on the risk of resistance to antiepileptic drugs: a meta-analysis of the literature. Genet Test Mol Biomarkers. 2014; 18: 106-111.
37. Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci. 2006; 8: 311-321.
38. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009; 82: A99-109.
39. Januchowski R, Zawierucha P, Ruciński M., et al. Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Pharmacother. 2014; 68: 447-453.
40. Januchowski R, Zawierucha P, Andrzejewska M., et al. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother. 2013; 67: 240-245.
41. Ryan DM, Carst O. Antibiotic assays in muscle: are conventional tissue levels misleading as indicator of the antibacterial activity? Scand J Infect Dis. 1980; 12: 307-309.
42. Ryan DM, Carst O. A problem in the interpretation of β-lactam antibiotic levels in tissues. J Antimicrobial Chemotherapy. 1983; 12: 281-284.
43. Burkhardt O, Brunner M, Schmidt S., et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrobial Chemotherapy. 2006; 58: 632-636.
44. Morrogh M, Olvera N, Bogomolniy F., et al. Tissue preparation for laser capture microdissection and RNA extraction from fresh frozen breast tissue. Biotechniques. 2007; 43: 41-42.
45. Bevilacqua C, Makhzami S, Helbling JC., et al. Maintaining RNA integrity in a homogeneous population of mammary epithelial cells isolated by laser capture microdissection. BMC Cell Biol. 2010; 11: 95.
46. Sluka P, ODonnell L, McLachlan RI., et al. Application of laser capture microdissection to analysis of gene expression in the testis. Prog Histochem Cytochem. 2008; 42: 173-201.
47. Ohbayashi M, Yamamoto C, Shiozawa A., et al. Differential mRNA expression and the uptake of methotrexate in primary MAEC and MLF cells: involvement of the Abc and Slco/Oatp transporters in alveolar epithelial cell toxicity. J Toxicol Sci. 2013; 38: 103-114.
48. Yee JY, Limenta LM, Rogers K., et al. Ensuring good quality RNA for quantitative real-time PCR isolated from renal proximal tubular cells using laser capture microdissection. BMC Res Notes. 2014; 7: 62.
49. Zhang W, Mojsilovic-Petrovic J, Andrade MF., et al. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. Faseb J. 2003; 17: 2085-2087.
50. Lundberg E, Fagerberg L, Klevebring D., et al. Defining the transcriptome and proteome in three functionally different human cell lines. Mol Syst Biol. 2010; 6: 450.
51. Tanaka AR, Abe-Dohmae S, Ohnishi T., et al. Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis. J Biol Chem. 2003; 278: 8815-8819.
52. Tournier N, Saba W, Cisternino S, Peyronneau MA., et al. Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide. AAPS J. 2013; 15: 1082-1090.
53. Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003; 2: 685-698.
54. Lai Y, Varma M, Feng B., et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability-considerations for drug development. Expert Opin Drug Metab Toxicol. 2012; 8: 723-743.
55. Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014; 10: 1337-1354.
56. Aller SG, Yu J, Ward A., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009; 323: 1718-1722. New York, NY.
57. Gonzalez TP, Mucenic T, Brenol JC., et al. ABCB1 C1236T, G2677T/A and C3435T polymorphisms in systemic lupus erythematosus patients. Braz J Med Biol Res. 2008; 41: 769-772.
58. Hitzl M, Drescher S, Van Der Kuip H., et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001; 11: 293-298.
59. Mechetner E, Kyshtoobayeva A, Zonis S., et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 1998; 4: 389-398.
60. Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Archiv. 2007; 453: 621-641.
61. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Rev. 2006; 86: 849-899.
62. Yin JY, Huang Q, Yang Y., et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics. 2009; 19: 206-216.
63. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Archiv. 2007; 453: 643-659.
64. Rau T, Erney B, Gores R., et al. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clinical Pharmacol Ther. 2006; 80: 468-476.
65. Benz-de Bretagne I, Respaud R, Vourch P., et al. Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans. Journal Biomed Biotechnol. 2011; 2011: 1-9.
66. Maliepaard M, Scheffer GL, Faneyte IF., et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001; 61: 3458-3464.
67. Keskitalo JE, Zolk O, Fromm MF., et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009; 86: 197-20.
68. Warren RB, Smith RL, Campalani E., et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008; 128: 1925-1929.
69. Diestra JE, Scheffer GL, Catala I., et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol. 2002; 198: 213-219.
70. Robey RW, Polgar O, Deeken J., et al. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007; 26: 39-57.
71. Kim YH, Ishii G, Goto K., et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer. 2009; 65: 105-111.
72. Jani M, Makai I, Kis E., et al. Ivermectin interacts with human ABCG2. J Pharm Sci. 2011; 100: 94-97.
73. Nies AT, Koepsell H, Winter S., et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009; 50: 1227-1240.
74. Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011; 10: 531-539.
75. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004; 308: 2-9.
76. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Archiv. 2004; 447: 666-676.
77. Lautem A, Heise M, Gräsel A., et al. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol. 2013; 42: 1297-1304.
78. Müller J, Lips KS, Metzner L., et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005; 70: 1851-1860.
79. Wang ZJ, Yin OQ, Tomlinson B., et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008; 18: 637-645.
80. Wu X, Kekuda R, Huang W., et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998; 273: 32776-32786.
81. Sakata T, Anzai N, Kimura T., et al. Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. J Pharmacol Sci. 2010; 113: 263-266.
82. Inazu M, Takeda H, Matsumiya T. Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J Neurochem. 2003; 84: 43-52.
83. Sata R, Ohtani H, Tsujimoto M., et al. Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther. 2005; 315: 888-895.
84. Lips KS, Volk C, Schmitt BM., et al. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol. 2005; 33: 79-88.
85. Li L, He M, Zhou L., et al. A solute carrier family 22 member 3 variant rs3088442 G→A associated with coronary heart disease inhibits lipopolysaccharide-induced inflammatory response. J Biol Chem. 2015; 290: 5328-5340.
86. Eraly SA. Organic anion transporter 3 inhibitors as potential novel antihypertensives. Pharmacol Res. 2008; 58: 257-261.
87. Urban TJ, Brown C, Castro RA., et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008; 83: 416-421.
88. Tokuhiro S, Yamada R, Chang X., et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet. 2003; 35: 341-348.
89. Peltekova VD, Wintle RF, Rubin LA., et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004; 36: 471-475.
90. Toh DS, Koo SH, Limenta LM., et al. Genetic variations of the SLC22A4 gene in Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2009; 24: 475-481.
91. Nakamura T, Nakanishi T, Haruta T., et al. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010; 7: 187-195.
92. Toh DS, Yee JY, Koo SH., et al. Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010; 25: 112-119.
93. Grube M, Meyer Zu Schwabedissen H., et al. Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos. 2005; 33: 31-37.
94. Hosoyamada M, Sekine T, Kanai Y., et al. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999; 276: F122-861.
95. Han YF, Fan XH, Wang XJ., et al. Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. Am J Hypertens. 2011; 24: 340-346.
96. Ueo H, Motohashi H, Katsura T., et al. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005; 70: 1104-1113.
97. Sweet DH, Miller DS, Pritchard JB., et al. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem. 2002; 277: 26934-26943.
98. Erdman AR, Mangravite LM, Urban TJ., et al. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol. 2006; 290: F905-12.
99. Kullak-Ublick GA, Ismair MG, Stieger B., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001; 120: 525-533.
100. Marciante KD, Durda JP, Heckbert SR., et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011; 21: 280-288.
101. Muck W, Mai I, Fritsche L., et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther. 1999; 65: 251-261.
102. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006; 112: 71-105.
103. Konig J, Cui Y, Nies AT., et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 2000; 278: G156-64.
104. Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics. 2004; 14: 441-452.
105. Chae YJ, Lee KR, Noh CK., et al. Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population. J Pharm Sci. 2012; 101: 1302-1313.
106. Kullak-Ublick GA, Stieger B, Hagenbuch B., et al. Hepatic transport of bile salts. Semin Liver Dis. 2000; 20: 273-292.
107. Meyer Zu Schwabedissen HE, Verstuyft C, Hk K., et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010; 298: F997-F1005.
108. Omote H, Hiasa M, Matsumoto T., et al. The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci. 2006; 27: 587-593.
109. Moriyama Y, Hiasa M, Matsumoto T., et al. Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica. 2008; 38: 1107-1118.
110. Nishimura K, Ide R, Hirota T., et al., et al. Identification and functional characterization of novel nonsynonymous variants in the human multidrug and toxin extrusion 2-K. Drug Metab Dispos. 2014; 42: 1432-1437.
111. Masuda S, Terada T, Yonezawa A., et al. Identification and functional characterization of a new human kidney-specificH+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006; 17: 2127-2135.
112. Ivliev AE, T Hoen PAC, Van Roon-Mom WMC., et al. Exploring the transcriptome of ciliated cells using in silico dissection of human tissues. PLoS One. 2012; 7: e35618.
113. Staud F, Cerveny L, Ahmadimoghaddam D., et al. Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics. Int J Biochem Cell Biol. 2013; 45: 2007-2011.
114. Borst P, Evers R, Kool M., et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000; 92: 1295-1302.
115. Sakaeda T, Nakamura T, Horinouchi M., et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001; 18: 1400-1404.
116. Kafka A, Sauer G, Jaeger C., et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003; 22: 1117-1121.
117. Brumme ZL, Dong WW, Chan KJ., et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. Aids. 2003; 17: 201-208.
118. Balram C, Sharma A, Sivathasan C., et al. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003; 56: 78-83.
119. Wang D, Johnson AD, Papp AC., et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005; 15: 693-704.
120. Létourneau IJ, Deeley RG, Cole SP. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics. 2005; 15: 647-657.
121. Chen L, Hong C, Chen EC., et al. Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J. 2013; 13: 110-120.
122. Toh DS, Murray M, Pern Tan K., et al. Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochem Pharmacol. 2011; 82: 1692-1699.
123. Liu R, Tang AM, Tan YL., et al. Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects. Eur J Clin Pharmacol. 2009; 65: 65-70.
124. Lee E, Ryan S, Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005; 78: 330-341.
125. Duan LP, Wang HH, Ohashi A., et al. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G269-76.
126. Kim IW, Han N, Burckart GJ., et al. Epigenetic changes in gene expression for drug-metabolizing enzymes and transporters. Pharmacotherapy. 2014; 34: 140-150.
127. Szyf M. Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics. 2004; 2: 357-377.
128. Desiderato L, Davey MW, Piper AA. Demethylation of the human MDR1 5′ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet. 1997; 23: 391-400.
129. El-Osta A, Kantharidis P, Zalcberg JR., et al. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol. 2002; 22: 1844-1857.
130. Kantharidis P, El-Osta A, Desilva M., et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res. 1997; 3: 2025-2032.
131. Nakayama M, Wada M, Harada T., et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood. 1998; 92: 4296-4307.
132. Shannon BA, Iacopetta BJ. Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Lett. 2001; 167: 91-97.
133. Tada Y, Wada M, Kuroiwa K., et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res. 2000; 6: 4618-4627.
134. Baker EK, El-Osta A. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing. Methods Mol Biol. 2010; 596: 183-198.
135. Reed K, Hembruff SL, Laberge ML., et al. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells. Epigenetics. 2008; 3: 270-280.
136. Aoki M, Terada T, Kajiwara M., et al. Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. Am J Physiol Renal Physiol. 2008; 295: F165-70.
137. Imai S, Kikuchi R, Kusuhara H., et al. Analysis of DNA methylation and histone modification profiles of liver-specific transporters. Mol Pharmacol. 2009; 75: 568-576.
138. Canfrán-Duque A, Pastor O, Quintana-Portillo R., et al. Curcumin promotes exosomes/microvesicles secretion that attenuates lysosomal cholesterol traffic impairment. Mol Nutr Food Res. 2014; 58: 687-697.
139. Lv YC, Yin K, Fu YC., et al. Posttranscriptional regulation of ATP-binding cassette transporter A1 in lipid metabolism. DNA Cell Biol. 2013; 32: 348-358.
140. Haenisch S, Werk AN, Cascorbi I. MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol. 2014; 77: 587-596.
141. Ikemura K, Iwamoto T, Okuda M. MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier function. Pharmacol Ther. 2014; 143: 217-224.
142. Meiler S, Baumer Y, Toulmin E., et al. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler Thromb Vasc Biol. 2015; 35: 323-331.
143. Zhao R, Feng J, He G. miR-613 regulates cholesterol efflux by targeting LXR and ABCA1 in PPARγ activated THP-1 macrophages. Biochem Biophys Res Commun. 2014; 448: 329-334.
144. Kang MH, Zhang LH, Wijesekara N., et al. Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler Thromb Vasc Biol. 2013; 33: 2724-2732.
145. Adlakha YK, Khanna S, Singh R., et al. Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXR expression and cholesterol homeostasis. Cell Death Dis. 2013; 4: e780.
146. De Aguiar Vallim TQ, Tarling EJ, Kim T., et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013; 112: 1602-1612.
147. Chen S, Chen X, Xiu Y-L., et al. microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells. J Ovarian Res. 2014; 7: 84.
148. Zong C, Wang J, Shi TM. MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumour Biol. 2014; 35: 12151-12156.
149. Shang Y, Zhang Z, Liu Z., et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014; 33: 3267-3276.
150. Chen Z, Ma T, Huang C., et al. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Cell Signal. 2013; 25: 2693-2701.
151. Yang T, Zheng ZM, Li XN., et al. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood). 2013; 238: 1024-1032.
152. Dong Z, Zhong Z, Yang L., et al. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 2014; 343: 249-257.
153. Werk AN, Bruckmueller H, Haenisch S., et al. Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. Pharmacogenet Genomics. 2014; 24: 283-291.
154. Markova SM, Kroetz DL. ABCC4 is regulated by microRNA-124a and microRNA-506. Biochem Pharmacol. 2014; 87: 515-522.
155. Zhu Y, Yu F, Jiao Y., et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 2011; 17: 7105-7115.
156. Shi L, Wang Z, Sun G., et al. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med. 2014; 16: 517-528.
157. Ma MT, He M, Wang Y., et al. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 2013; 339: 107-115.
158. Shen WW, Zeng Z, Zhu WX., et al. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl). 2013; 91: 989-1000.
159. Li WQ, Li YM, Tao BB., et al. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit. 2010; 16: HY27-30.
160. Moradi Sarabi M, Doosti M, Einollahi N., et al. Effect of eicosapentaenoic acid on the expression of ABCG1 gene in the human monocyte THP-1 cells. Acta Med Iran. 2014; 52: 176-181.
161. Helal O, Berrougui H, Loued S., et al. Extra-virgin olive oil consumption improves the capacity of HDL to mediate cholesterol efflux and increases ABCA1 and ABCG1 expression in human macrophages. Br J Nutr. 2013; 109: 1844-1855.
162. Leclercq S, Skrzypski J, Courvoisier A., et al. Effect of dietary polyunsaturated fatty acids on the expression of peroxisomal ABC transporters. Biochimie. 2008; 90: 1602-1607.
163. Calpe-Berdiel L, Escolà-Gil JC, Ribas V., et al. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis. 2005; 181: 75-85.
164. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2008; 23: 22-44.
165. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005; 20: 452-477.
166. Guidotti A, Auta J, Davis J., et al. Toward the identification of peripheral epigenetic biomarkers of schizophrenia. J.Neurogenet. 2014; 28: 41-52.